- Home
- AVIR vs CMPS Comparison
AVIR vs CMPS Comparison
Compare AVIR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CMPS
- Stock Information
- Founded
- AVIR 2012
- CMPS 2020
- Country
- AVIR United States
- CMPS United Kingdom
- Employees
- AVIR N/A
- CMPS N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- CMPS Health Care
- Exchange
- AVIR Nasdaq
- CMPS Nasdaq
- Market Cap
- AVIR 247.5M
- CMPS 280.2M
- IPO Year
- AVIR 2020
- CMPS 2020
- Fundamental
- Price
- AVIR $3.29
- CMPS $4.00
- Analyst Decision
- AVIR Hold
- CMPS Strong Buy
- Analyst Count
- AVIR 1
- CMPS 6
- Target Price
- AVIR $6.88
- CMPS $33.60
- AVG Volume (30 Days)
- AVIR 491.5K
- CMPS 705.9K
- Earning Date
- AVIR 11-07-2024
- CMPS 10-31-2024
- Dividend Yield
- AVIR N/A
- CMPS N/A
- EPS Growth
- AVIR N/A
- CMPS N/A
- EPS
- AVIR N/A
- CMPS N/A
- Revenue
- AVIR N/A
- CMPS N/A
- Revenue This Year
- AVIR N/A
- CMPS N/A
- Revenue Next Year
- AVIR N/A
- CMPS N/A
- P/E Ratio
- AVIR N/A
- CMPS N/A
- Revenue Growth
- AVIR N/A
- CMPS N/A
- 52 Week Low
- AVIR $2.75
- CMPS $3.86
- 52 Week High
- AVIR $4.60
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- AVIR 49.07
- CMPS 37.40
- Support Level
- AVIR $3.10
- CMPS $3.86
- Resistance Level
- AVIR $3.27
- CMPS $4.91
- Average True Range (ATR)
- AVIR 0.16
- CMPS 0.28
- MACD
- AVIR 0.02
- CMPS -0.01
- Stochastic Oscillator
- AVIR 55.28
- CMPS 16.59
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.